ArticleGeburtshilfe und Frauenheilkunde2026
INTERLACE Study: Real-world Data for Germany Based on a Case Series of Patients with Locally Advanced Cervical Cancer.
Article in Geburtshilfe und Frauenheilkunde, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary chemoradiotherapy is the established and standard treatment for locally advanced cervical cancer. The INTERLACE study investigated the impact of adding induction chemotherapy with six cycles of carboplatin AUC2 and paclitaxel 80 mg/m Methods: Patients treated according to the INTERLACE scheme at the University Medical Center Hamburg-Eppendorf between October 2023 and December 2024 were evaluated and described. Results: Seven patients with advanced cervical cancer (ECOG 0-1, median age 37 years, 43% FIGO stage IB1/2) treated with the INTERLACE regimen were identified during the study period. All patients received six cycles of the planned induction chemotherapy. The median time between completion of chemotherapy and the start of radiotherapy was 10 days, with the total duration of treatment varying between 43 and 63 days. All patients were able to complete radiotherapy using tele- and brachytherapy. 43% received all 5-6 cycles of cisplatin, 86% received at least four cycles of cisplatin simultaneously with radiotherapy. There were various reasons for discontinuing concomitant chemotherapy (1 hematological, 3 non-hematological).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.